

Resource Summary Report

Generated by RRID on Aug 3, 2026

PE/Cyanine7 anti-mouse CD103

RRID:AB_2563690

Type: Antibody

Proper Citation

BioLegend Cat# 121425, RRID:AB_2563690

Antibody Information

URL: http://antibodyregistry.org/AB_2563690

Proper Citation: BioLegend Cat# 121425, RRID:AB_2563690

Target Antigen: CD103

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-mouse CD103

Description: This monoclonal targets CD103

Target Organism: mouse

Clone ID: Clone 2E7

Antibody ID: AB_2563690

Vendor: BioLegend

Catalog Number: 121425

Alternative Catalog Numbers: 121426

Record Creation Time: 20250820T014407+0000

Record Last Update: 20250820T114304+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse CD103.

No alerts have been found for PE/Cyanine7 anti-mouse CD103.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8+T cell dysfunction via FGF21-driven lipolysis. *Cell reports*, 44(11), 116526.

Ciccone MF, et al. (2025) Loss of BPTF restores estrogen response and suppresses metastasis of mammary tumors. *Nature communications*, 16(1), 9168.

Tursi NJ, et al. (2025) Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity. *Cell reports. Medicine*, 6(4), 102035.

Vasquez JH, et al. (2025) Somatic Miwi2 modulates mitochondrial function in airway multiciliated cells and exacerbates influenza pathogenesis. *iScience*, 28(4), 112291.

Green WD, et al. (2025) Enhancer-driven gene regulatory networks reveal transcription factors governing T cell adaptation and differentiation in the tumor microenvironment. *Immunity*, 58(7), 1725.

Benamar M, et al. (2025) Notch3 destabilizes regulatory T cells to drive autoimmune neuroinflammation in multiple sclerosis. *Immunity*, 58(11), 2753.

Frey HC, et al. (2025) A membrane lipid signature unravels the dynamic landscape of group 1 innate lymphoid cells across the health-disease continuum. *iScience*, 28(3), 112043.

Huang CX, et al. (2024) Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. *Cancer cell*, 42(12), 2082.

Hu C, et al. (2024) Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells. *Cell metabolism*, 36(3), 630.

Hänggi K, et al. (2024) Interleukin-1 β release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. *Cancer cell*, 42(12), 2015.

Dan J, et al. (2023) Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. *Cell reports. Medicine*, 4(10), 101229.

Bhaskar A, et al. (2023) SIRT2 inhibition by AGK2 enhances mycobacteria-specific stem cell memory responses by modulating beta-catenin and glycolysis. *iScience*, 26(5), 106644.

Guendel F, et al. (2020) Group 3 Innate Lymphoid Cells Program a Distinct Subset of IL-22BP-Producing Dendritic Cells Demarcating Solitary Intestinal Lymphoid Tissues. *Immunity*, 53(5), 1015.

Zhang H, et al. (2020) CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. *Cancer cell*, 37(1), 37.